Fig. 2

Validation and confirmation of LEP methylation in AML. a The genomic coordinates (GC) of LEP promoter region CpG island and primer locations. The panel plots the GC content as a percentage of the total. Each vertical bar in the bottom panel represents the presence of a CpG dinucleotide. Black horizontal lines indicate regions amplified by sequencing primer pairs and qMSP primer pairs. CpGplot (http://emboss.bioinformatics.nl/cgi-bin/emboss/cpgplot) and Methyl Primer Express v1.0 software were used for creating the figure. TSS transcription start site, qMSP real-time quantitative methylation-specific PCR; b LEP methylation level in controls and AML patients detected by targeted bisulfite sequencing. c Correlation between targeted bisulfite sequencing and qMSP results for LEP methylation in AML patients. The correlation analysis was conducted by Spearman test. d LEP methylation level in controls and AML patients examined by qMSP. AML included de novo AML and sAML which indicated MDS-derived AML. e LEP expression level in controls and AML patients. LEP expression level was examined by qPCR. f ROC curve analysis of LEP methylation distinguishing AML from controls